Physician profile
Iris J Lee
NPI 1861593782
$7,250.84
in general payments reported to CMS, 2019-2025
15 companies · $2,433 in 2025
The $2,433 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2022: $4,398 · 2023: $119 · 2024: $120 · 2025: $2,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Food and Beverage | $571.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,490.00 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $2,254.19 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $128.81 | 2022-2023 | Lupkynis |
| Covidien LP | $97.67 | 2019 | |
| Vifor Pharma, INC. | $83.64 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $39.96 | 2025 | Envarsus |
| Ardelyx, INC. | $33.38 | 2025 | Ibsrela |
| Novo Nordisk INC | $24.35 | 2025 | Rivfloza |
| Travere Therapeutics, INC. | $22.40 | 2025 | |
| Apellis Pharmaceuticals, INC. | $20.36 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $19.63 | 2025 | Livtencity |
| Amgen INC. | $18.24 | 2025 | Tavneos |
| Boston Scientific Corporation | $18.21 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.